Skip to main content
Fig. 2 | BMC Ophthalmology

Fig. 2

From: Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy

Fig. 2

Mean CRT measured by OCT at the 3-month follow-up was 580.18 ± 257.04 μm, with an average decrease of 114.95 ± 237.21 μm compared to baseline, which represented a significant decrease (p < 0.01). At the 12-month follow-up, the mean CRT was 593.58 ± 243.64 μm. The mean decrease was 101.55 ± 256.07 μm compared to baseline (p < 0.01). Error bars indicate the upper and lower bounds of the 95% CIs. *Significant statistical difference (p < 0.05). **Significant statistical difference (p < 0.01) between groups

Back to article page